Received the approval notice for re-registration of Orlistat Capsules
February 20, 2025
Source: drugdu
35
On February 17, Watson Pharmaceuticals announced that the company recently received the "Drug Re-registration Approval Notice" for the company's product Orlistat Capsules approved and issued by the Chongqing Municipal Drug Administration. The drug approval number of Orlistat Capsules is valid until January 22, 2030. The product was originally a cooperative product of the company. At the end of 2021, the company reached a further agreement with its partners to sell and operate Orlistat Capsules under its own brand "Quchang". At present, this variety has little impact on the company's operating income and profits. It will not have a significant impact on the company's operating performance in the short term.
https://finance.eastmoney.com/a/202502173321214653.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Seizing the opportunity of the Chinese market, multinational pharmaceutical companies saw revenue growth last year February 21, 2025
- Can Chengda Bio turn the tide? February 21, 2025
- A drop of blood can predict Alzheimer’s disease 15 years in advance. When can it be realized? February 21, 2025
- collision of targets and technologies February 21, 2025
- When can a drop of blood predict Alzheimer’s disease 15 years in advance| Shanghai Acceleration Run February 20, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
